雷喹莫特局部用药在蕈样肉芽肿肿瘤分期中的潜在应用

IF 0.9 Q4 CHEMISTRY, PHYSICAL

Current Organocatalysis Pub Date : 2023-07-31 DOI:10.2174/2213337210666230731162414

A. Boretti

{"title":"雷喹莫特局部用药在蕈样肉芽肿肿瘤分期中的潜在应用","authors":"A. Boretti","doi":"10.2174/2213337210666230731162414","DOIUrl":null,"url":null,"abstract":"\n\nResiquimod (formula C17H22N4O2, ChEMBL Id 383322) is an immune response modifier that stimulates immune responses to tumor lesions mostly through toll-like receptors (TLR) 7 and 8 dependent pathways.\n\n\n\nThis study considers the potential use of Resiquimod in the topical treatment of mycosis fungoides tumor stage, for which standard-of-care is radiation therapy which has a very well-known dosage-effects relationship and efficacy, but also side effects, and also the limitation regarding the number of times a same area can be treated during a lifetime.\n\n\n\nTrials are suggested to evaluate the use of Resiquimod as a replacement for radiation therapy in case of shallow lesions, as well as a supporting agent to increase the efficacy and reduce the dosage of the radiation therapy, lessening the side effects, and permitting many more uses for a same treatment zone.\n\n\n\nThis study proposes more research for the possible use of Resiquimod in the standalone or synergetic treatment of MF tumor phase, as there is potential, but not yet evidence, for these uses\n","PeriodicalId":10945,"journal":{"name":"Current Organocatalysis","volume":null,"pages":null},"PeriodicalIF":0.9000,"publicationDate":"2023-07-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Potential uses of topical Resiquimod for Mycosis Fungoides tumor stage\",\"authors\":\"A. Boretti\",\"doi\":\"10.2174/2213337210666230731162414\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\\n\\nResiquimod (formula C17H22N4O2, ChEMBL Id 383322) is an immune response modifier that stimulates immune responses to tumor lesions mostly through toll-like receptors (TLR) 7 and 8 dependent pathways.\\n\\n\\n\\nThis study considers the potential use of Resiquimod in the topical treatment of mycosis fungoides tumor stage, for which standard-of-care is radiation therapy which has a very well-known dosage-effects relationship and efficacy, but also side effects, and also the limitation regarding the number of times a same area can be treated during a lifetime.\\n\\n\\n\\nTrials are suggested to evaluate the use of Resiquimod as a replacement for radiation therapy in case of shallow lesions, as well as a supporting agent to increase the efficacy and reduce the dosage of the radiation therapy, lessening the side effects, and permitting many more uses for a same treatment zone.\\n\\n\\n\\nThis study proposes more research for the possible use of Resiquimod in the standalone or synergetic treatment of MF tumor phase, as there is potential, but not yet evidence, for these uses\\n\",\"PeriodicalId\":10945,\"journal\":{\"name\":\"Current Organocatalysis\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.9000,\"publicationDate\":\"2023-07-31\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Current Organocatalysis\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.2174/2213337210666230731162414\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"CHEMISTRY, PHYSICAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Organocatalysis","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/2213337210666230731162414","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"CHEMISTRY, PHYSICAL","Score":null,"Total":0}

引用次数: 0

摘要

雷喹莫特（式C17H22N4O2，ChEMBL Id 383322）是一种免疫反应调节剂，主要通过toll样受体（TLR）7和8依赖性途径刺激对肿瘤病变的免疫反应。本研究考虑了雷喹莫特在蕈样肉芽肿肿瘤分期局部治疗中的潜在用途，其护理标准是放射治疗，放射治疗具有非常众所周知的剂量-效果关系和疗效，但也有副作用，以及一生中同一区域治疗次数的限制。建议进行试验，以评估在浅层病变的情况下使用雷喹莫特作为放射治疗的替代品，以及作为辅助剂来提高疗效和减少放射治疗的剂量，减轻副作用，并允许在同一治疗区域使用更多药物。这项研究建议对Resiquimod在MF肿瘤期的单独或协同治疗中的可能用途进行更多研究，因为这些用途有潜力，但尚未有证据

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Potential uses of topical Resiquimod for Mycosis Fungoides tumor stage

Resiquimod (formula C17H22N4O2, ChEMBL Id 383322) is an immune response modifier that stimulates immune responses to tumor lesions mostly through toll-like receptors (TLR) 7 and 8 dependent pathways. This study considers the potential use of Resiquimod in the topical treatment of mycosis fungoides tumor stage, for which standard-of-care is radiation therapy which has a very well-known dosage-effects relationship and efficacy, but also side effects, and also the limitation regarding the number of times a same area can be treated during a lifetime. Trials are suggested to evaluate the use of Resiquimod as a replacement for radiation therapy in case of shallow lesions, as well as a supporting agent to increase the efficacy and reduce the dosage of the radiation therapy, lessening the side effects, and permitting many more uses for a same treatment zone. This study proposes more research for the possible use of Resiquimod in the standalone or synergetic treatment of MF tumor phase, as there is potential, but not yet evidence, for these uses

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Current Organocatalysis CHEMISTRY, PHYSICAL-

CiteScore

2.00

自引率

0.00%

发文量

期刊介绍： Current Organocatalysis is an international peer-reviewed journal that publishes significant research in all areas of organocatalysis. The journal covers organo homogeneous/heterogeneous catalysis, innovative mechanistic studies and kinetics of organocatalytic processes focusing on practical, theoretical and computational aspects. It also includes potential applications of organocatalysts in the fields of drug discovery, synthesis of novel molecules, synthetic method development, green chemistry and chemoenzymatic reactions. This journal also accepts papers on methods, reagents, and mechanism of a synthetic process and technology pertaining to chemistry. Moreover, this journal features full-length/mini review articles within organocatalysis and synthetic chemistry. It is the premier source of organocatalysis and synthetic methods related information for chemists, biologists and engineers pursuing research in industry and academia.